Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

NCT04421664 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT04421664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04421664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 3
Overall status
Terminated
Start date
March 25, 2020
Completion date
August 17, 2020
Enrollment
70 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, coronavirus, sars-cov infection